Axoft vs BRYM

Axoft vs BRYM, compared side by side on 9 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Axoft is on 62/100 and BRYM on 37/100.

AxoftA neurotechnology company developing implantable Brain-Computer Interfaces.
BRYMWearable neurofeedback platform for cognitive performance improvement.

Where each one leads

Axoft

  • our overall score: 62/100 against 37/100
  • funding raised: $55.0M against $650K

BRYM

Leads on none of the measures we hold for both companies.

At a glance

MeasureAxoftBRYM
What it isA neurotechnology company developing implantable Brain-Computer Interfaces.Wearable neurofeedback platform for cognitive performance improvement.
CategoryNeurotechnology, Biotechnology, Medical Devices, Artificial IntelligenceNeurotechnology, Wearable Technology, Cognitive Performance, Workplace Wellbeing
Sells toBusiness modelB2BB2B
OfferingHardwareHardware
HeadquartersCambridge, USAStockholm, Sweden
StatusActiveActive

Size, funding and growth

MeasureAxoftBRYM
Total funding$55.0M$650K
Latest roundSeries APre-Seed

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureAxoftBRYM
StartupHub scoreOur 0-100 rating62/10037/100
TractionNot published29/100
TeamNot published30/100
QualityNot published48/100

Axoft vs BRYM: common questions

Which is better, Axoft or BRYM?

On our 0-100 score Axoft rates higher (62/100 against 37/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 9 data points above: read the rows that match what you are buying for.

How do Axoft and BRYM compare on the numbers?

Axoft leads on our overall score (62/100 against 37/100), funding raised ($55.0M against $650K).

Read the full Axoft review and pricing or the BRYM review and pricing. You can also browse other Axoft alternatives we track.